183 related articles for article (PubMed ID: 31857678)
21. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
Hwang HS; Kim D; Choi J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
[TBL] [Abstract][Full Text] [Related]
22. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
[TBL] [Abstract][Full Text] [Related]
23. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
[TBL] [Abstract][Full Text] [Related]
24. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
[TBL] [Abstract][Full Text] [Related]
25. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
[TBL] [Abstract][Full Text] [Related]
26. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
[TBL] [Abstract][Full Text] [Related]
27. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
[TBL] [Abstract][Full Text] [Related]
28. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.
Jansen AM; van Wezel T; van den Akker BE; Ventayol Garcia M; Ruano D; Tops CM; Wagner A; Letteboer TG; Gómez-García EB; Devilee P; Wijnen JT; Hes FJ; Morreau H
Eur J Hum Genet; 2016 Jul; 24(7):1089-92. PubMed ID: 26648449
[TBL] [Abstract][Full Text] [Related]
29. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
[TBL] [Abstract][Full Text] [Related]
30. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
[TBL] [Abstract][Full Text] [Related]
31. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
[TBL] [Abstract][Full Text] [Related]
32. Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
Weber CAM; Krönke N; Volk V; Auber B; Förster A; Trost D; Geffers R; Esmaeilzadeh M; Lalk M; Nabavi A; Samii A; Krauss JK; Feuerhake F; Hartmann C; Wiese B; Brand F; Weber RG
Acta Neuropathol Commun; 2023 Nov; 11(1):184. PubMed ID: 37990341
[TBL] [Abstract][Full Text] [Related]
33. Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk.
Mur P; Magraner-Pardo L; García-Mulero S; Díez-Villanueva A; Del Valle J; Ezquerro E; Lázaro C; Capellá G; Moreno V; Sanz-Pamplona R; Pons T; Valle L
Eur J Hum Genet; 2022 Apr; 30(4):485-489. PubMed ID: 34285382
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
35. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.
Valle L; Hernández-Illán E; Bellido F; Aiza G; Castillejo A; Castillejo MI; Navarro M; Seguí N; Vargas G; Guarinos C; Juarez M; Sanjuán X; Iglesias S; Alenda C; Egoavil C; Segura Á; Juan MJ; Rodriguez-Soler M; Brunet J; González S; Jover R; Lázaro C; Capellá G; Pineda M; Soto JL; Blanco I
Hum Mol Genet; 2014 Jul; 23(13):3506-12. PubMed ID: 24501277
[TBL] [Abstract][Full Text] [Related]
36. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract][Full Text] [Related]
37. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers.
Briggs S; Tomlinson I
J Pathol; 2013 Jun; 230(2):148-53. PubMed ID: 23447401
[TBL] [Abstract][Full Text] [Related]
38. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
Chubb D; Broderick P; Frampton M; Kinnersley B; Sherborne A; Penegar S; Lloyd A; Ma YP; Dobbins SE; Houlston RS
J Clin Oncol; 2015 Feb; 33(5):426-32. PubMed ID: 25559809
[TBL] [Abstract][Full Text] [Related]
39. Role of POLE and POLD1 in familial cancer.
Mur P; García-Mulero S; Del Valle J; Magraner-Pardo L; Vidal A; Pineda M; Cinnirella G; Martín-Ramos E; Pons T; López-Doriga A; Belhadj S; Feliubadaló L; Munoz-Torres PM; Navarro M; Grau E; Darder E; Llort G; Sanz J; Ramón Y Cajal T; Balmana J; Brunet J; Moreno V; Piulats JM; Matías-Guiu X; Sanz-Pamplona R; Aligué R; Capellá G; Lázaro C; Valle L
Genet Med; 2020 Dec; 22(12):2089-2100. PubMed ID: 32792570
[TBL] [Abstract][Full Text] [Related]
40. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
